Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Intensity Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 2 | 10 | +8 |
| Shares | 28.6K | 298.4K | +269.9K (+944.9%) |
| Value | $170.2K | $1.19M | +$1.02M (+599.2%) |
New holders (9)
Institutions that held Intensity Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Hohimer Wealth Management, LLC | 186,464 | $740.3K | 0.21% |
| Sigma Planning Corp | 48,144 | $191.1K | 0.01% |
| Millennium Management LLC | 24,822 | $101.3K | 0.00% |
| Geode Capital Management, LLC | 23,070 | $94.2K | 0.00% |
| BlackRock Inc. | 10,239 | $40.6K | 0.00% |
| Wells Fargo & Company | 2,480 | $9.85K | 0.00% |
| Advisor Group Holdings, Inc. | 2,000 | $7.94K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,027 | $4.29K | 0.00% |
| JPMorgan Chase & Co | 1 | $4 | 0.00% |
Sold out (1)
Institutions that held Intensity Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Walleye Capital LLC | 28,363 | $169.0K |